fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Blueprint Medicines showcases Ayvakit® data highlighting survival benefits and disease-modifying potential in systemic mastocytosis at ASH 2024

Written by | 10 Dec 2024

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the… read more.

Novo Nordisk to present 13 abstracts at ASH 2024 including phase 2/3 HIBISCUS trial of etavopivat

Written by | 9 Dec 2024

Novo Nordisk announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society… read more.

New insights on Haemophilia A and rare blood diseases to be presented by Sobi® at ASH 2024

Written by | 5 Dec 2024

New data from Sobi® and partners will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA (USA) from the… read more.

Novartis highlights transformative oncology research with 65+ abstracts at ASH and SABCS 2024

Written by | 26 Nov 2024

Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San… read more.

Merck to showcase breakthrough data on hematologic malignancies at ASH 2024

Written by | 24 Nov 2024

Merck known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented… read more.

ASH 2024: Johnson & Johnson showcases innovations in multiple myeloma, B-cell malignancies, and autoimmune disorders

Written by | 21 Nov 2024

Johnson & Johnson announced more than 90 abstracts featuring data from the Company’s differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH)… read more.

BMS to showcase 90+ data presentations at ASH 2024, highlighting innovations in hematology and cell therapy

Written by | 20 Nov 2024

BMS announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research… read more.

Autolus Therapeutics presents key data on Obecabtagene Autoleucel (obe-cel) at 2024 ASH Annual Meeting

Written by | 12 Nov 2024

Autolus Therapeutics announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held from December 7-10, 2024, in San… read more.

New insights on uproleselan for AML treatment to Be unveiled by GlycoMimetics at ASH 2024

Written by | 10 Nov 2024

GlycoMimetics, Inc. announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.